Dasatinib

Identification

Summary

Dasatinib is a tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia.

Brand Names

Sprycel

Generic Name

Dasatinib

DrugBank Accession Number

DB01254

Background

Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.^1,7 Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.^5,6 Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases.⁵

Unlike imatinib, another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.^2,5 Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance.² The use of dasatinib was first approved by the FDA in 2006.^7,9

Type

Small Molecule

Groups

Approved, Investigational

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Dasatinib (DB01254)

×

Close

Weight

Average: 488.006
Monoisotopic: 487.155721508

Chemical Formula

C₂₂H₂₆ClN₇O₂S

Synonyms

• Anh. dasatinib
• Anhydrous dasatinib
• BMS dasatinib
• Dasatinib
• Dasatinib (anh.)
• dasatinib (anhydrous)
• Dasatinib anhydrous
• Dasatinibum
• N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide

External IDs

• BMS-354825

Pharmacology

Indication

Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib is also indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL in combination with chemotherapy.⁷

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

• Accelerated Phase Chronic Myelogenous Leukemia (CML)
• Acute Lymphoblastic Leukaemias (ALL)
• Chronic Myelogenous Leukemia (CML) in Blast Crisis
• Chronic Phase Chronic Myeloid Leukemia

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Dasatinib is an orally available small-molecule multikinase inhibitor.⁵ During clinical trials, less than 1% of patients treated with dasatinib had QTc prolongation as an adverse reaction, and 1% experienced a QTcF higher than 500 ms. The use of dasatinib is also associated with myelosuppression, bleeding-related events, fluid retention, cardiovascular toxicity, pulmonary arterial hypertension, severe dermatologic reactions, tumor lysis syndrome and hepatotoxicity. It may also cause embryo-fetal toxicity and lead to adverse reactions associated with bone growth and development in pediatric patients.⁷

Mechanism of action

Dasatinib is a tyrosine kinase inhibitor with several targets. At nanomolar concentrations, it inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ.^1,5,7 In patients with chronic myeloid leukemia (CML), the tyrosine kinase activity of BCR-ABL is deregulated, leading to the growth, proliferation and survival of cancerous hematopoietic cells. Dasatinib binds to the active and inactive conformation of the ABL kinase domain with a higher affinity than imatinib.⁶ In chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL, dasatinib inhibits cell growth. Also, dasatinib has in vitro activity against leukemic cell lines that are either sensitive or resistant to imatinib.⁷ It has been suggested that dasatinib is able to overcome imatinib resistance caused by BCR-ABL kinase domain mutations because it does not require interaction with some of the residues involved in those mutations.^6,7

Target	Actions	Organism
ATyrosine-protein kinase ABL1	inhibitor multitarget	Humans
AProto-oncogene tyrosine-protein kinase Src	inhibitor multitarget	Humans
AEphrin type-A receptor 2	antagonist	Humans
ATyrosine-protein kinase Lck	inhibitor multitarget	Humans
ATyrosine-protein kinase Yes	inhibitor	Humans
AMast/stem cell growth factor receptor Kit	antagonist	Humans
APlatelet-derived growth factor receptor beta	antagonist	Humans
USignal transducer and activator of transcription 5B	inhibitor	Humans
UAbelson tyrosine-protein kinase 2	multitarget	Humans
ATyrosine-protein kinase Fyn	inhibitor multitarget	Humans
UTyrosine-protein kinase BTK	inhibitor	Humans
UNuclear receptor subfamily 4 group A member 3	inhibitor	Humans
ABreakpoint cluster region protein	inhibitor	Humans
UTyrosine-protein kinase CSK	inhibitor	Humans
UEphrin type-A receptor 5	inhibitor	Humans
UEphrin type-B receptor 4	inhibitor	Humans
UTyrosine-protein kinase Fgr	inhibitor	Humans
UTyrosine-protein kinase FRK	binder	Humans
UHeat shock cognate 71 kDa protein	binder	Humans
UTyrosine-protein kinase Lyn	inhibitor	Humans
UMitogen-activated protein kinase kinase kinase MLT	binder	Humans
UMitogen-activated protein kinase 14	binder	Humans
UAmidophosphoribosyltransferase	binder	Humans

Absorption

Dasatinib has a dose-proportional pharmacokinetic profile and a linear elimination between 15 mg/day (0.15 times the lowest approved recommended dose) and 240 mg/day (1.7 times the highest approved recommended dose). At 100 mg once a day, dasatinib has a C_max and AUC of 82.2 ng/mL and 397 ng/mL*hr, respectively. In healthy adult subjects given dasatinib as dispersed tablets in juice, the adjusted geometric mean ratio compared to intact tablets was 0.97 for C_max, and 0.84 for AUC. The T_max of dasatinib is between 0.5 and 6 hours following oral administration. Following a single dose of 100 mg, a high-fat meal increases the AUC of dasatinib by 14%.⁷

Volume of distribution

Dasatinib has an apparent volume of distribution of 2505 L.⁷

Protein binding

In vitro, the binding of dasatinib to human plasma proteins is approximately 96%.⁷

Metabolism

In humans, dasatinib is mainly metabolized by CYP3A4, although flavin-containing monooxygenase 3 (FMO3) and uridine diphosphate-glucuronosyltransferase (UGT) enzymes are also involved in the formation of dasatinib metabolites.⁷ Five pharmacologically active dasatinib metabolites have been identified: M4, M5, M6, M20 and M24. M4, M20, and M24 are mainly generated by CYP3A4, M5 is generated by FMO3, and M6 is generated by a cytosolic oxidoreductase.^3,4 M4 is equipotent to dasatinib and represents approximately 5% of the AUC. However, it is unlikely to play a major role in the observed pharmacology of dasatinib.^3,7 M5 and M6 are more than 10 times less active than dasatinib and are considered minor circulating metabolites.³

Hover over products below to view reaction partners

• Dasatinib
  • Dasatinib M4 metabolite
  • Dasatinib M5 metabolite
  • Dasatinib M24 metabolite
  • Dasatinib M20 metabolite
  • Dasatinib M6 metabolite

Route of elimination

Dasatinib is mainly eliminated via feces. Within 10 days, 4% of dasatinib is recovered in urine, while 85% is recovered in feces. Approximately 0.1% and 19% of the administered dasatinib dose was recovered unchanged in urine and feces, respectively, and the rest was recovered as metabolites.⁷

Half-life

The terminal half-life of dasatinib is 3-5 hours.⁷

Clearance

The clearance of dasatinib does not vary over time. Dasatinib has an apparent oral clearance of 363.8 L/hr.⁷

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Overdose cases with dasatinib occurred in isolated cases during clinical studies. Patients that received 280 mg of dasatinib per day for 1 week developed severe myelosuppression and bleeding. Since dasatinib is associated with severe myelosuppression, patients that ingest more than the recommended dosage should be monitored closely for myelosuppression and receive appropriate supportive treatment.⁷

Acute overdose in animals was associated with cardiotoxicity. In rodents, ventricular necrosis and valvular/ventricular/atrial hemorrhage were detected at single doses higher than or equal to 100 mg/kg (600 mg/m²). In monkeys receiving single doses higher than or equal to 10 mg/kg (120 mg/m²), there was a tendency for increased systolic and diastolic blood pressure.⁷ In rats, the oral LD₅₀ of dasatinib is 50-100 mg/kg, and in monkeys, it is 25-45 mg/kg.⁸

Pathways

Pathway	Category
Dasatinib Inhibition of BCR-ABL	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abametapir	The serum concentration of Dasatinib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Dasatinib can be increased when combined with Abatacept.
Abciximab	The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Abciximab.
Abemaciclib	The metabolism of Abemaciclib can be decreased when combined with Dasatinib.
Abiraterone	The serum concentration of Dasatinib can be increased when it is combined with Abiraterone.
Abrocitinib	The serum concentration of Dasatinib can be increased when it is combined with Abrocitinib.
Acalabrutinib	The metabolism of Acalabrutinib can be decreased when combined with Dasatinib.
Acenocoumarol	The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Acenocoumarol.
Acetaminophen	The metabolism of Dasatinib can be increased when combined with Acetaminophen.
Acetazolamide	The serum concentration of Dasatinib can be increased when it is combined with Acetazolamide.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

• Avoid grapefruit products. Grapefruit may reduce the CYP3A4 metabolism of dasatinib, increasing its serum levels.
• Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of dasatinib.
• Take with or without food. High fat meals may increase the AUC of dasatinib by to 14%; however, the product label recommends taking dasatinib with or without food.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Dasatinib monohydrate	RBZ1571X5H	863127-77-9	XHXFZZNHDVTMLI-UHFFFAOYSA-N

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Dasatinib Accord	Tablet, film coated	70 mg	Oral	Accord Healthcare S.L.U.	2022-05-04	2023-03-30
Dasatinib Accord	Tablet, film coated	100 mg	Oral	Accord Healthcare S.L.U.	2022-05-04	2023-03-30
Dasatinib Accord	Tablet, film coated	70 mg	Oral	Accord Healthcare S.L.U.	2022-05-04	2023-03-30
Dasatinib Accord	Tablet, film coated	50 mg	Oral	Accord Healthcare S.L.U.	2022-05-04	2023-03-30
Dasatinib Accord	Tablet, film coated	100 mg	Oral	Accord Healthcare S.L.U.	2022-05-04	2023-03-30
Dasatinib Accord	Tablet, film coated	140 mg	Oral	Accord Healthcare S.L.U.	2022-05-04	2023-03-30
Dasatinib Accord	Tablet, film coated	20 mg	Oral	Accord Healthcare S.L.U.	2022-05-04	2023-03-30
Dasatinib Accord	Tablet, film coated	80 mg	Oral	Accord Healthcare S.L.U.	2022-05-04	2023-03-30
Dasatinib Accord	Tablet, film coated	50 mg	Oral	Accord Healthcare S.L.U.	2022-05-04	2023-03-30
Dasatinib Accord	Tablet, film coated	100 mg	Oral	Accord Healthcare S.L.U.	2022-05-04	2023-03-30

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Apo-dasatinib	Tablet	100 mg	Oral	Apotex Corporation	2020-01-06	Not applicable
Apo-dasatinib	Tablet	80 mg	Oral	Apotex Corporation	2020-01-06	Not applicable
Apo-dasatinib	Tablet	50 mg	Oral	Apotex Corporation	2020-01-06	Not applicable
Apo-dasatinib	Tablet	70 mg	Oral	Apotex Corporation	2020-01-06	Not applicable
Apo-dasatinib	Tablet	20 mg	Oral	Apotex Corporation	2020-01-06	Not applicable
Reddy-dasatinib	Tablet	140 mg	Oral	Dr Reddy's Laboratories Ltd	2021-09-16	Not applicable
Reddy-dasatinib	Tablet	70 mg	Oral	Dr Reddy's Laboratories Ltd	2021-09-16	Not applicable
Reddy-dasatinib	Tablet	100 mg	Oral	Dr Reddy's Laboratories Ltd	2021-09-16	Not applicable
Reddy-dasatinib	Tablet	50 mg	Oral	Dr Reddy's Laboratories Ltd	2021-09-16	Not applicable
Reddy-dasatinib	Tablet	80 mg	Oral	Dr Reddy's Laboratories Ltd	2021-09-16	Not applicable

Categories

ATC Codes

L01EA02 — Dasatinib

• L01EA — BCR-ABL tyrosine kinase inhibitors
• L01E — PROTEIN KINASE INHIBITORS
• L01 — ANTINEOPLASTIC AGENTS
• L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Categories

• Antineoplastic Agents
• Antineoplastic and Immunomodulating Agents
• Bcr-Abl Tyrosine Kinase Inhibitors
• BCRP/ABCG2 Inhibitors
• BCRP/ABCG2 Substrates
• Cytochrome P-450 CYP1A2 Substrates
• Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors (weak)
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
• Cytochrome P-450 CYP3A5 Substrates
• Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index
• Cytochrome P-450 Enzyme Inhibitors
• Cytochrome P-450 Substrates
• Drugs causing inadvertant photosensitivity
• Enzyme Inhibitors
• Immunosuppressive Agents
• Kinase Inhibitor
• Myelosuppressive Agents
• Narrow Therapeutic Index Drugs
• P-glycoprotein inhibitors
• P-glycoprotein substrates
• P-glycoprotein substrates with a Narrow Therapeutic Index
• Photosensitizing Agents
• Potential QTc-Prolonging Agents
• Protein Kinase Inhibitors
• Pyrimidines
• QTc Prolonging Agents
• Sulfur Compounds
• Thiazoles
• Tyrosine Kinase Inhibitors

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Anilides

Direct Parent

Aromatic anilides

Alternative Parents

N-arylpiperazines / Thiazolecarboxamides / 2-heteroaryl carboxamides / Dialkylarylamines / 2,5-disubstituted thiazoles / Toluenes / Aminopyrimidines and derivatives / Chlorobenzenes / N-alkylpiperazines / 2-amino-1,3-thiazoles / Aryl chlorides / Imidolactams / Heteroaromatic compounds / Trialkylamines / Amino acids and derivatives / Secondary carboxylic acid amides / 1,2-aminoalcohols / Azacyclic compounds / Secondary amines / Hydrocarbon derivatives / Organopnictogen compounds / Primary alcohols / Organochlorides / Organic oxides

show 14 more

Substituents

1,2-aminoalcohol / 1,3-thiazol-2-amine / 1,4-diazinane / 2,5-disubstituted 1,3-thiazole / 2-heteroaryl carboxamide / Alcohol / Alkanolamine / Amine / Amino acid or derivatives / Aminopyrimidine / Aromatic anilide / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Azole / Carboxamide group / Carboxylic acid derivative / Chlorobenzene / Dialkylarylamine / Halobenzene / Heteroaromatic compound / Hydrocarbon derivative / Imidolactam / N-alkylpiperazine / N-arylpiperazine / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organochloride / Organohalogen compound / Organoheterocyclic compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Piperazine / Primary alcohol / Pyrimidine / Secondary amine / Secondary carboxylic acid amide / Tertiary aliphatic amine / Tertiary amine / Thiazole / Thiazolecarboxamide / Thiazolecarboxylic acid or derivatives / Toluene

show 36 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

tertiary amino compound, N-arylpiperazine, N-(2-hydroxyethyl)piperazine, aminopyrimidine, monocarboxylic acid amide, organochlorine compound, 1,3-thiazole, secondary amino compound (CHEBI:49375)

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

X78UG0A0RN

CAS number

302962-49-8

InChI Key

ZBNZXTGUTAYRHI-UHFFFAOYSA-N

InChI

InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

IUPAC Name

N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide

SMILES

CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1

References

Synthesis Reference

US6596746

General References

1. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. [Article]
2. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41. [Article]
3. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA: Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008 Jul;36(7):1357-64. doi: 10.1124/dmd.107.018267. Epub 2008 Apr 17. [Article]
4. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [Article]
5. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [Article]
6. Aguilera DG, Tsimberidou AM: Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag. 2009 Apr;5(2):281-9. Epub 2009 May 4. [Article]
7. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (February 2023) [Link]
8. Bristol Myers Squibb: Dasatinib SDS [Link]
9. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

External Links

Human Metabolome Database

HMDB0015384

KEGG Drug

D03658

PubChem Compound

3062316

PubChem Substance

46505143

ChemSpider

2323020

BindingDB

13216

RxNav

1546019

ChEBI

49375

ChEMBL

CHEMBL1421

ZINC

ZINC000003986735

Therapeutic Targets Database

DAP000004

PharmGKB

PA162372878

PDBe Ligand

1N1

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Dasatinib

PDB Entries

2gqg / 2y6o / 2zva / 3g5d / 3lfa / 3oht / 3qlg / 3sxr / 4qms / 4xey …

show 11 more

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Chronic Phase Chronic Myeloid Leukemia	2
4	Not Yet Recruiting	Treatment	Multiple Myeloma (MM)	1
4	Recruiting	Treatment	BCR-ABL / Chronic Myelogenous Leukemia (CML) / Dasatinib	1
4	Recruiting	Treatment	Chronic Myelogenous Leukemia (CML) / Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)	1
4	Recruiting	Treatment	Chronic Phase Chronic Myeloid Leukemia	1
4	Unknown Status	Treatment	Chronic Myelogenous Leukemia (CML)	1
4	Unknown Status	Treatment	Neoplasms, Hematologic	1
4	Unknown Status	Treatment	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)	1
3	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukemia, Pediatric	1
3	Active Not Recruiting	Treatment	Acute Myeloid Leukemia	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

• Bristol-Myers Squibb Co.
• E.R. Squibb and Sons LLC
• Physicians Total Care Inc.

Dosage Forms

Form	Route	Strength
Tablet	Oral	100 mg
Tablet	Oral	50 mg
Tablet	Oral	70 mg
Tablet	Oral	80 mg
Tablet, film coated	Oral
Tablet, film coated	Oral	100 MG
Tablet, film coated	Oral	20 MG
Tablet, film coated	Oral	50 MG
Tablet, film coated	Oral	70 MG
Tablet, film coated	Oral	80 MG
Tablet, film coated	Oral	140 MG
Tablet	Oral	20 mg
Powder, for suspension	Oral	10 MG/ML
Tablet	Oral	100 mg/1
Tablet	Oral	140 mg/1
Tablet	Oral	20 mg/1
Tablet	Oral	20.000 mg
Tablet	Oral	50 mg/1
Tablet	Oral	70 mg/1
Tablet	Oral	80 mg/1
Tablet, coated	Oral	100 mg
Tablet, coated	Oral	140 mg
Tablet, coated	Oral	20 mg
Tablet, coated	Oral	50 mg
Tablet, coated	Oral	70 mg
Tablet, film coated	Oral	50 mg per tab
Tablet	Oral	140 mg

Prices

Unit description	Cost	Unit
Sprycel 100 mg tablet	278.24USD	tablet
Sprycel 50 mg tablet	139.12USD	tablet
Sprycel 70 mg tablet	139.12USD	tablet
Sprycel 20 mg tablet	69.56USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
CA2366932	No	2009-08-25	2020-04-12
US6596746	Yes	2003-07-22	2020-12-28
US7125875	Yes	2006-10-24	2020-10-13
US7153856	Yes	2006-12-26	2020-10-28
US7491725	Yes	2009-02-17	2026-09-28
US8680103	Yes	2014-03-25	2025-08-04

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	280-286 °C	FDA label
logP	1.8	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0128 mg/mL	ALOGPS
logP	2.77	ALOGPS
logP	4.01	Chemaxon
logS	-4.6	ALOGPS
pKa (Strongest Acidic)	10.99	Chemaxon
pKa (Strongest Basic)	7.19	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	8	Chemaxon
Hydrogen Donor Count	3	Chemaxon
Polar Surface Area	106.51 Å2	Chemaxon
Rotatable Bond Count	7	Chemaxon
Refractivity	133.08 m3·mol-1	Chemaxon
Polarizability	50.39 Å3	Chemaxon
Number of Rings	4	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	Yes	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9852
Blood Brain Barrier	-	0.507
Caco-2 permeable	-	0.5638
P-glycoprotein substrate	Substrate	0.6562
P-glycoprotein inhibitor I	Inhibitor	0.5371
P-glycoprotein inhibitor II	Inhibitor	0.5425
Renal organic cation transporter	Non-inhibitor	0.7288
CYP450 2C9 substrate	Non-substrate	0.7061
CYP450 2D6 substrate	Non-substrate	0.8152
CYP450 3A4 substrate	Substrate	0.5704
CYP450 1A2 substrate	Non-inhibitor	0.5612
CYP450 2C9 inhibitor	Inhibitor	0.8008
CYP450 2D6 inhibitor	Non-inhibitor	0.8358
CYP450 2C19 inhibitor	Inhibitor	0.574
CYP450 3A4 inhibitor	Inhibitor	0.7295
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.8343
Ames test	Non AMES toxic	0.7185
Carcinogenicity	Non-carcinogens	0.7308
Biodegradation	Not ready biodegradable	0.9863
Rat acute toxicity	2.4772 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8538
hERG inhibition (predictor II)	Inhibitor	0.718

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-000m-0390000000-8a413cb9e53d14cbe10a
MS/MS Spectrum - , positive	LC-MS/MS	splash10-000i-0011900000-4dac51b915117532ebe0

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	0.26	N/A	N/A	A28672
IC 50 (nM)	0.8	N/A	N/A	A27749
IC 50 (nM)	14	N/A	N/A	A20064
IC 50 (nM)	4.2	N/A	N/A	A29597
Kd (nM)	0.016	N/A	N/A	A28058
Kd (nM)	0.019	N/A	N/A	A28058
Kd (nM)	0.025	N/A	N/A	A28058
Kd (nM)	0.029	N/A	N/A	A28058
Kd (nM)	0.032	N/A	N/A	A28058
Kd (nM)	0.037	N/A	N/A	A28058
Kd (nM)	0.041	N/A	N/A	A28058
Kd (nM)	0.046	N/A	N/A	A28058
Kd (nM)	0.047	N/A	N/A	A28058
Kd (nM)	0.058	N/A	N/A	A28058
Kd (nM)	0.064	N/A	N/A	A28058
Kd (nM)	0.1	N/A	N/A	A28058
Kd (nM)	0.53	N/A	N/A	A28055
Kd (nM)	0.72	N/A	N/A	A28055
Kd (nM)	0.96	N/A	N/A	A28055
Kd (nM)	1.1	N/A	N/A	A28055
Kd (nM)	1.2	N/A	N/A	A28055
Kd (nM)	120	N/A	N/A	A28058
Kd (nM)	2.1	N/A	N/A	A28055
Kd (nM)	590	N/A	N/A	A28055
Kd (nM)	890	N/A	N/A	A28058

Details

Binding Properties1. Tyrosine-protein kinase ABL1

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inhibitor

Multitarget

General Function

Syntaxin binding

Specific Function

Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility a...

Gene Name

ABL1

Uniprot ID

P00519

Uniprot Name

Tyrosine-protein kinase ABL1

Molecular Weight

122871.435 Da

References

1. Piccaluga PP, Paolini S, Martinelli G: Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer. 2007 Sep 15;110(6):1178-86. [Article]
2. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. [Article]
3. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41. [Article]
4. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	0.5	N/A	N/A	A29598
IC 50 (nM)	0.6	N/A	N/A	A29599 / A27749 / A29600
IC 50 (nM)	1.5	N/A	N/A	A29597
IC 50 (nM)	14	N/A	N/A	A29599
Kd (nM)	0.21	N/A	N/A	A28055 / A28058

Details

Binding Properties2. Proto-oncogene tyrosine-protein kinase Src

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inhibitor

Multitarget

General Function

Sh3/sh2 adaptor activity

Specific Function

Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion recept...

Gene Name

SRC

Uniprot ID

P12931

Uniprot Name

Proto-oncogene tyrosine-protein kinase Src

Molecular Weight

59834.295 Da

References

1. Kamath AV, Wang J, Lee FY, Marathe PH: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. Epub 2007 Apr 11. [Article]
2. Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG: Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5. [Article]
3. Quintas-Cardama A, Kantarjian H, Cortes J: Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol. 2006 Dec;2(6):655-65. [Article]
4. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006 Jan 1;66(1):473-81. [Article]
5. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R: Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005 Oct 15;65(20):9185-9. [Article]
6. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	137	N/A	N/A	A29601
Kd (nM)	0.85	N/A	N/A	A28055 / A28058

Details

Binding Properties3. Ephrin type-A receptor 2

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Antagonist

General Function

Transmembrane receptor protein tyrosine kinase activity

Specific Function

Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. Th...

Gene Name

EPHA2

Uniprot ID

P29317

Uniprot Name

Ephrin type-A receptor 2

Molecular Weight

108265.585 Da

References

1. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [Article]
2. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA: Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008 Jul;36(7):1357-64. doi: 10.1124/dmd.107.018267. Epub 2008 Apr 17. [Article]
3. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	0.4	N/A	N/A	A29598
IC 50 (nM)	0.4	7	22	A2224
IC 50 (nM)	3	N/A	N/A	A29602
IC 50 (nM)	4	N/A	N/A	A27749
Kd (nM)	0.2	N/A	N/A	A28055 / A28058

Details

Binding Properties4. Tyrosine-protein kinase Lck

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inhibitor

Multitarget

General Function

Sh2 domain binding

Specific Function

Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-ce...

Gene Name

LCK

Uniprot ID

P06239

Uniprot Name

Tyrosine-protein kinase Lck

Molecular Weight

58000.15 Da

References

1. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. [Article]
2. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [Article]
3. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	0.5	N/A	N/A	A29598
Kd (nM)	0.3	N/A	N/A	A28055 / A28058

Details

Binding Properties5. Tyrosine-protein kinase Yes

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inhibitor

General Function

Receptor binding

Specific Function

Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by rece...

Gene Name

YES1

Uniprot ID

P07947

Uniprot Name

Tyrosine-protein kinase Yes

Molecular Weight

60800.78 Da

References

1. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE: Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006 Mar;168(3):962-72. [Article]
2. Margutti S, Laufer SA: Are MAP kinases drug targets? Yes, but difficult ones. ChemMedChem. 2007 Aug;2(8):1116-40. [Article]
3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [Article]
4. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

Details6. Mast/stem cell growth factor receptor Kit

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Antagonist

General Function

Transmembrane receptor protein tyrosine kinase activity

Specific Function

Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell main...

Gene Name

KIT

Uniprot ID

P10721

Uniprot Name

Mast/stem cell growth factor receptor Kit

Molecular Weight

109863.655 Da

References

1. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006 Jan 1;66(1):473-81. [Article]
2. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C: Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286-91. Epub 2006 Jan 24. [Article]
3. Dizdar O, Dede DS, Bulut N, Altundag K: Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines. Breast Cancer Res Treat. 2008 Jan;107(2):303. Epub 2007 Mar 10. [Article]
4. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	28	N/A	N/A	A29598
Kd (nM)	0.63	N/A	N/A	A28055 / A28058

Details

Binding Properties7. Platelet-derived growth factor receptor beta

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Antagonist

General Function

Vascular endothelial growth factor binding

Specific Function

Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic...

Gene Name

PDGFRB

Uniprot ID

P09619

Uniprot Name

Platelet-derived growth factor receptor beta

Molecular Weight

123966.895 Da

References

1. Zhang Z, Meier KE: New assignments for multitasking signal transduction inhibitors. Mol Pharmacol. 2006 May;69(5):1510-2. Epub 2006 Feb 23. [Article]
2. Chen Z, Lee FY, Bhalla KN, Wu J: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006 May;69(5):1527-33. Epub 2006 Jan 25. [Article]
3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [Article]
4. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

Details8. Signal transducer and activator of transcription 5B

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

General Function

Transcription factor activity, sequence-specific dna binding

Specific Function

Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activa...

Gene Name

STAT5B

Uniprot ID

P51692

Uniprot Name

Signal transducer and activator of transcription 5B

Molecular Weight

89865.35 Da

References

1. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K: Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006 Oct 1;12(19):5869-78. [Article]
2. Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R: Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther. 2007 Apr;6(4):1400-5. [Article]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
Kd (nM)	0.17	N/A	N/A	A28055 / A28058

Details

Binding Properties9. Abelson tyrosine-protein kinase 2

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Multitarget

General Function

Receptor binding

Specific Function

Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, ce...

Gene Name

ABL2

Uniprot ID

P42684

Uniprot Name

Abelson tyrosine-protein kinase 2

Molecular Weight

128341.935 Da

References

1. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [Article]
2. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G: The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. Epub 2007 Aug 7. [Article]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
Kd (nM)	0.79	N/A	N/A	A28055 / A28058

Details

Binding Properties10. Tyrosine-protein kinase Fyn

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inhibitor

Multitarget

General Function

Protein tyrosine kinase activity

Specific Function

Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remode...

Gene Name

FYN

Uniprot ID

P06241

Uniprot Name

Tyrosine-protein kinase Fyn

Molecular Weight

60761.49 Da

References

1. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [Article]
2. Lee D, Park YH, Lee JE, Kim HS, Min KY, Jo MG, Kim HS, Choi WS, Kim YM: Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice. Biomol Ther (Seoul). 2020 Sep 1;28(5):456-464. doi: 10.4062/biomolther.2020.013. [Article]
3. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	1.3	N/A	N/A	A20064
IC 50 (nM)	5	N/A	N/A	A20064 / A29604
Kd (nM)	1.4	N/A	N/A	A28055 / A28058

Details

Binding Properties11. Tyrosine-protein kinase BTK

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

General Function

Protein tyrosine kinase activity

Specific Function

Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately le...

Gene Name

BTK

Uniprot ID

Q06187

Uniprot Name

Tyrosine-protein kinase BTK

Molecular Weight

76280.71 Da

References

1. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G: The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. Epub 2007 Aug 7. [Article]
2. Kaliamurthi S, Selvaraj G, Selvaraj C, Singh SK, Wei DQ, Peslherbe GH: Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19. Int J Mol Sci. 2021 Jun 30;22(13). pii: ijms22137071. doi: 10.3390/ijms22137071. [Article]

Details12. Nuclear receptor subfamily 4 group A member 3

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

General Function

Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes (By similarity). Plays a role in the regulation of proliferation, survival and differentiation of many different cell types and also in metabolism and inflammation. Mediates proliferation of vascular smooth muscle, myeloid progenitor cell and type B pancreatic cells; promotes mitogen-induced vascular smooth muscle cell proliferation through transactivation of SKP2 promoter by binding a NBRE site (By similarity). Upon PDGF stimulation, stimulates vascular smooth muscle cell proliferation by regulating CCND1 and CCND2 expression. In islets, induces type B pancreatic cell proliferation through up-regulation of genes that activate cell cycle, as well as genes that cause degradation of the CDKN1A (By similarity). Negatively regulates myeloid progenitor cell proliferation by repressing RUNX1 in a NBRE site-independent manner. During inner ear, plays a role as a key mediator of the proliferative growth phase of semicircular canal development (By similarity). Mediates also survival of neuron and smooth muscle cells; mediates CREB-induced neuronal survival, and during hippocampus development, plays a critical role in pyramidal cell survival and axonal guidance. Is required for S phase entry of the cell cycle and survival of smooth muscle cells by inducing CCND1, resulting in RB1 phosphorylation. Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription (By similarity). Plays also a role in inflammation; upon TNF stimulation, mediates monocyte adhesion by inducing the expression of VCAM1 and ICAM1 by binding to the NBRE consensus site (By similarity) (PubMed:20558821). In mast cells activated by Fc-epsilon receptor cross-linking, promotes the synthesis and release of cytokines but impairs events leading to degranulation (By similarity). Plays also a role in metabolism; by modulating feeding behavior; and by playing a role in energy balance by inhibiting the glucocorticoid-induced orexigenic neuropeptides AGRP expression, at least in part by forming a complex with activated NR3C1 on the AGRP- glucocorticoid response element (GRE), and thus weakening the DNA binding activity of NR3C1. Upon catecholamines stimulation, regulates gene expression that controls oxidative metabolism in skeletal muscle (By similarity). Plays a role in glucose transport by regulating translocation of the SLC2A4 glucose transporter to the cell surface (PubMed:24022864). Finally, during gastrulation plays a crucial role in the formation of anterior mesoderm by controlling cell migration. Inhibits adipogenesis (By similarity). Also participates in cardiac hypertrophy by activating PARP1 (By similarity).

Specific Function

Core promoter sequence-specific dna binding

Gene Name

NR4A3

Uniprot ID

Q92570

Uniprot Name

Nuclear receptor subfamily 4 group A member 3

Molecular Weight

68229.025 Da

References

1. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G: The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. Epub 2007 Aug 7. [Article]

Details13. Breakpoint cluster region protein

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inhibitor

General Function

Rho guanyl-nucleotide exchange factor activity

Specific Function

GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity.

Gene Name

BCR

Uniprot ID

P11274

Uniprot Name

Breakpoint cluster region protein

Molecular Weight

142818.07 Da

References

1. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16;305(5682):399-401. [Article]
2. Reddy EP, Aggarwal AK: The ins and outs of bcr-abl inhibition. Genes Cancer. 2012 May;3(5-6):447-54. doi: 10.1177/1947601912462126. [Article]
3. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]
4. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
Kd (nM)	1	N/A	N/A	A28055 / A28058

Details

Binding Properties14. Tyrosine-protein kinase CSK

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

General Function

Receptor binding

Specific Function

Non-receptor tyrosine-protein kinase that plays an important role in the regulation of cell growth, differentiation, migration and immune response. Phosphorylates tyrosine residues located in the C...

Gene Name

CSK

Uniprot ID

P41240

Uniprot Name

Tyrosine-protein kinase CSK

Molecular Weight

50703.975 Da

References

1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]
2. Kwarcinski FE, Fox CC, Steffey ME, Soellner MB: Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine. ACS Chem Biol. 2012 Nov 16;7(11):1910-7. doi: 10.1021/cb300337u. Epub 2012 Sep 5. [Article]

Details15. Ephrin type-A receptor 5

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

General Function

Transmembrane-ephrin receptor activity

Specific Function

Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The ...

Gene Name

EPHA5

Uniprot ID

P54756

Uniprot Name

Ephrin type-A receptor 5

Molecular Weight

114802.31 Da

References

1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]
2. Wang X, Zhang M, Ping F, Liu H, Sun J, Wang Y, Shen A, Ding J, Geng M: Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma. Hepatology. 2019 Feb;69(2):573-586. doi: 10.1002/hep.29792. Epub 2018 Mar 24. [Article]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
Kd (nM)	0.34	N/A	N/A	A28055 / A28058

Details

Binding Properties16. Ephrin type-B receptor 4

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

General Function

Transmembrane receptor protein tyrosine kinase activity

Specific Function

Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The...

Gene Name

EPHB4

Uniprot ID

P54760

Uniprot Name

Ephrin type-B receptor 4

Molecular Weight

108269.26 Da

References

1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]
2. Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C: PDGFRbeta reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6383-8. doi: 10.1073/pnas.1403608111. Epub 2014 Apr 14. [Article]

Details17. Tyrosine-protein kinase Fgr

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

General Function

Protein tyrosine kinase activity

Specific Function

Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocy...

Gene Name

FGR

Uniprot ID

P09769

Uniprot Name

Tyrosine-protein kinase Fgr

Molecular Weight

59478.11 Da

References

1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]
2. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. [Article]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
Kd (nM)	0.31	N/A	N/A	A28055 / A28058

Details

Binding Properties18. Tyrosine-protein kinase FRK

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Binder

General Function

Receptor binding

Specific Function

Non-receptor tyrosine-protein kinase that negatively regulates cell proliferation. Positively regulates PTEN protein stability through phosphorylation of PTEN on 'Tyr-336', which in turn prevents i...

Gene Name

FRK

Uniprot ID

P42685

Uniprot Name

Tyrosine-protein kinase FRK

Molecular Weight

58253.61 Da

References

1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]

Details19. Heat shock cognate 71 kDa protein

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Binder

General Function

Unfolded protein binding

Specific Function

Acts as a repressor of transcriptional activation. Inhibits the transcriptional coactivator activity of CITED1 on Smad-mediated transcription. Chaperone. Component of the PRP19-CDC5L complex that f...

Gene Name

HSPA8

Uniprot ID

P11142

Uniprot Name

Heat shock cognate 71 kDa protein

Molecular Weight

70897.565 Da

References

1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
Kd (nM)	0.57	N/A	N/A	A28055 / A28058

Details

Binding Properties20. Tyrosine-protein kinase Lyn

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

General Function

Receptor signaling protein tyrosine kinase activity

Specific Function

Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, respons...

Gene Name

LYN

Uniprot ID

P07948

Uniprot Name

Tyrosine-protein kinase Lyn

Molecular Weight

58573.595 Da

References

1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]
2. Lee D, Park YH, Lee JE, Kim HS, Min KY, Jo MG, Kim HS, Choi WS, Kim YM: Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice. Biomol Ther (Seoul). 2020 Sep 1;28(5):456-464. doi: 10.4062/biomolther.2020.013. [Article]
3. FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006) [Link]

Details21. Mitogen-activated protein kinase kinase kinase MLT

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Binder

General Function

Protein serine/threonine kinase activity

Specific Function

Stress-activated component of a protein kinase signal transduction cascade. Regulates the JNK and p38 pathways. Pro-apoptotic. Role in regulation of S and G2 cell cycle checkpoint by direct phospho...

Gene Name

ZAK

Uniprot ID

Q9NYL2

Uniprot Name

Mitogen-activated protein kinase kinase kinase MLT

Molecular Weight

91154.315 Da

References

1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
Kd (nM)	27	N/A	N/A	A28055 / A28058
Kd (nM)	495	N/A	N/A	A29603

Details

Binding Properties22. Mitogen-activated protein kinase 14

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Binder

General Function

Protein serine/threonine kinase activity

Specific Function

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellu...

Gene Name

MAPK14

Uniprot ID

Q16539

Uniprot Name

Mitogen-activated protein kinase 14

Molecular Weight

41292.885 Da

References

1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]

Details23. Amidophosphoribosyltransferase

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Binder

General Function

Metal ion binding

Specific Function

Not Available

Gene Name

PPAT

Uniprot ID

Q06203

Uniprot Name

Amidophosphoribosyltransferase

Molecular Weight

57398.52 Da

References

1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [Article]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at May 09, 2007 00:32 / Updated at October 02, 2023 21:58